Fosun Pharma told the Shanghai Stock Exchange that it will jointly invest up to 100 million U.S. dollars to produce vaccines with a German company, and the company will provide patents and technical knowledge.
Mexico City (apro). -Local media reported that the Chinese pharmaceutical company Fosun Pharma has reached an agreement with its German partner BioNTech, which will produce 1 billion doses of Pfizer-BioNTech vaccine against COVID-19 each year.
Pfizer BioNTech’s vaccine is one of the most effective vaccines against coronavirus in the world, accounting for about 95%.
Fosun Pharma told the Shanghai Stock Exchange on Sunday that it will invest up to 100 million U.S. dollars to produce this vaccine with BioNTech, and BioNTech will provide patents and technical knowledge.
According to the agreement, Fosun has the exclusive right to supply vaccines in Mainland China, Hong Kong, Macau and Taiwan.
BioNTech today also announced plans to move its Asian headquarters to Singapore and establish a factory in Singapore, which will “provide regional and global supply capabilities” and “rapidly respond to production capabilities.”
Hong Kong and Macau have approved the use of Pfizer BioNTech in emergency situations, although the vaccine has not yet been approved by the Beijing authorities for use in mainland China.
The Chinese government may give Pfizer the green light for its COVID-19 vaccine in July next year, making it the first foreigners in the country to be approved.
So far, China has approved five national vaccines against the coronavirus, and these vaccines have made it available to more than 317 million people.
Beijing plans to vaccinate 40% of its residents by the end of June next year. (Information from Efe)